Bridgewater-based Cosette Pharmaceuticals said on Monday that Jeff Neubig has been appointed as vice president, Quality and Regulatory Affairs.
Prior to joining Cosette, Neubig served as vice president of Quality and Regulatory Affairs, North America at LTS Lohmann Therapy Systems, where he successfully oversaw multiple regulatory inspections with zero observations, provided regulatory guidance and wrote filings for IND, NDA and ANDA products, and led tech transfer and validation teams, among other achievements.
“We are thrilled to add an experienced quality and regulatory leader like Jeff to Cosette, further establishing our unwavering commitment to delivering high quality, reliable products that has resulted in 24 new product launches over the last three years with zero major quality observations,” Apurva Saraf, president and CEO, Cosette Pharmaceuticals said. “As we scale our business exponentially, Jeff’s proven track record in quality leadership and regulatory strategy will be instrumental in delivering affordable and accessible therapies with speed and precision.”
“I’m excited to be joining Cosette at this time of strong momentum and progress to help bring critical therapies to patients,” Neubig said. “Cosette is widely known and respected for being a high-quality, reliable supplier of medicines. I’m thrilled to help advance that important work and lay the foundation for continued long-term growth.”
Neubig brings over 35 years of experience in the pharmaceutical industry to Cosette, including over 25 years leading quality assurance, quality control and regulatory affairs teams, working with products from pre-clinical development all the way through commercial operations. He has worked in companies specializing in transdermal patches, oral thin films, liquid formulations, sterile injectables and solid oral dosage forms.
